BRAF and skin cancer: When each indication was classified further according to BRAF, RAS mutation status, or wild-type (no RAF or RAS mutations), the strength of the correlations appeared to diminish, though still significant, with skin cancer remaining the most sensitive indication to cobimetinib treatment (Fig. 2b).